NMN vs NADH: Which NAD Support Is Better?

When people search for NMN vs NADH, they are usually trying to answer one question: which supplement actually raises cellular NAD⁺ in a way that matters? Both compounds sit in the same biochemical pathway, yet they enter the body through different gates and face different fates in the gut and bloodstream. The distinction is not academic. It determines whether the molecule you swallow ever reaches the tissues where NAD⁺ is actually consumed.

What the Research Actually Shows

The human evidence for NMN is still early, but it is growing and methodologically stronger than the data for NADH. As of this writing, no large-scale, long-term RCT has directly compared NMN and NADH head-to-head in humans. What we have are separate study tracks, and they are not equivalent.

NMN has been tested in multiple randomized, placebo-controlled trials in humans. Yoshino et al. (2021) treated prediabetic women with 250 mg NMN daily for ten weeks and reported improved muscle insulin sensitivity measured by hyperinsulinemic-euglycemic clamp. Igarashi et al. (2022) gave healthy older men 250–500 mg NMN daily for twelve weeks and observed increased gait speed, grip strength, and auditory acuity alongside elevated blood NAD⁺ metabolite levels. Liao et al. (2021) used 300–600 mg daily in amateur runners for six weeks and found dose-dependent increases in aerobic capacity. Irie et al. (2020) administered 100–500 mg to healthy Japanese men and confirmed dose-dependent rises in blood NMN and NAD⁺ metabolites without serious adverse events. Niu et al. (2023) reported changes in serum metabolism and telomere length in a pre-aging cohort after sixty days of supplementation.

NADH, by contrast, has a thinner human trial record. Most published studies are smaller, shorter, or lack the biomarker confirmation that the supplement raised tissue NAD⁺. Some trials focus on fatigue or mood outcomes rather than NAD⁺ kinetics. That does not mean NADH is useless; it means the evidentiary bar is lower, and mechanistic clarity is weaker.

Preclinical work provides the backdrop. Gomes et al. (2013) showed that declining NAD⁺ during aging disrupts nuclear-mitochondrial communication via sirtuin-dependent and pseudohypoxic pathways. This foundational Cell paper established why restoring NAD⁺ matters, but it did not test NMN or NADH directly in humans. It is a rationale, not proof of efficacy for either supplement.

How the Biochemistry Differs

NAD⁺ is not a static reservoir. It is a coenzyme that cycles constantly between oxidized (NAD⁺) and reduced (NADH) states during glycolysis, the citric acid cycle, and oxidative phosphorylation. Every unit of NAD⁺ is consumed and regenerated thousands of times per day. The relevant question for supplementation is not whether you have NAD⁺ in a test tube, but whether the compound you ingest can raise the intracellular NAD⁺ pool in vivo.

NMN is a direct precursor. It is one enzymatic step away from NAD⁺: nicotinamide mononucleotide is phosphorylated by NMN adenylyltransferase to form NAD⁺ inside the cell. Animal studies suggest that NMN can be absorbed intact from the gut or converted to nicotinamide riboside (NR) at the intestinal surface and then re-phosphorylated back to NMN before entering circulation. In humans, Irie et al. (2020) detected intact NMN in plasma after oral administration, supporting the idea that at least some fraction reaches the bloodstream without full degradation.

NADH is the reduced, electron-carrying form of NAD⁺. It is not a precursor in the anabolic sense; it is the product of NAD⁺ reduction. When you ingest NADH, the molecule must first be oxidized back to NAD⁺ before it can participate in the NAD⁺-consuming reactions that sirtuins and PARPs depend on. The gut and liver are highly reductive environments, and oral NADH is thought to be largely oxidized or degraded during first-pass metabolism. Some researchers have proposed that NADH may act as an antioxidant or mitochondrial electron donor independently of NAD⁺ salvage, but this is not the same mechanism as raising NAD⁺ pools.

The pharmacokinetic gap is real. NMN has been shown to raise blood NAD⁺ metabolites in humans at doses of 100–500 mg. NADH has not demonstrated comparable, dose-dependent NAD⁺ elevation in peer-reviewed human pharmacokinetic studies. That distinction should guide form selection.

Comparing the Evidence Side by Side

Feature	NMN	NADH
Human RCTs with NAD+ biomarker data	Multiple (Irie 2020; Yoshino 2021; Igarashi 2022; Liao 2021; Niu 2023)	Limited; few studies measure NAD+ metabolites
Typical studied dose range	100–600 mg/day	5–10 mg/day (often sublingual or enteric-coated)
Primary mechanism supported by human data	Direct NAD+ precursor via NMNAT	Uncertain; possible direct electron donor or partial oxidation to NAD+
Key functional outcomes in RCTs	Insulin sensitivity, muscle function, aerobic capacity, gait speed	Fatigue, mood (smaller trials; mixed quality)
Evidence quality for NAD+ elevation	Moderate to high	Low to moderate
Form availability	Capsule, powder, sublingual	Tablet, sublingual, enteric-coated

The table above is not a verdict. It is a map of what is known and what is not. If your goal is to raise NAD⁺ with the best current human evidence, NMN is the stronger candidate. If you are considering NADH for other reasons—such as its proposed role in chronic fatigue or as a mitochondrial electron shuttle—those are separate questions with their own, thinner evidence base.

What the Evidence Does Not Show

It is important to state the boundaries clearly. None of the NMN trials have shown reversal of aging in humans. Yoshino et al. (2021) improved insulin sensitivity in prediabetic women, but the effect size was modest and the study was ten weeks. Igarashi et al. (2022) found functional improvements in older men, yet the sample was small and the study was not powered for hard clinical endpoints. Liao et al. (2021) enhanced aerobic capacity in runners, but these were healthy, trained individuals, not frail elderly patients. Niu et al. (2023) reported metabolic and telomere changes, but the study was short and the clinical significance of the telomere finding is unclear.

There is also no human evidence that NMN extends lifespan. The longevity data are entirely from yeast, worms, and rodents. Translating those findings to humans requires assumptions that may not hold. NADH has even less longevity-relevant data. Any marketing claim that either supplement "reverses aging" or "extends life" in humans is unsupported by peer-reviewed evidence.

Another gap: we do not know the optimal dose, the best duration, or whether continuous use is superior to cycling. The human trials used 100–600 mg daily for 6–12 weeks. Whether higher doses, longer durations, or combination with other precursors (such as NR or nicotinamide) offer additional benefit is unknown. The same uncertainty applies to NADH.

Who Benefits Most

The strongest human evidence for NMN currently sits in three populations: older adults with early functional decline, individuals with prediabetic insulin resistance, and healthy adults seeking performance or metabolic optimization. Igarashi et al. (2022) targeted healthy older men and saw improvements in gait speed and grip strength—measures that predict falls, independence, and mortality in aging. Yoshino et al. (2021) focused on prediabetic women and improved muscle insulin sensitivity, a clinically meaningful endpoint given the global burden of type 2 diabetes. Liao et al. (2021) studied amateur runners and found aerobic gains, suggesting utility for active middle-aged adults.

NADH has been studied more often in fatigue-related conditions, such as chronic fatigue syndrome or fibromyalgia, but the trials are small and heterogeneous. If your primary complaint is low energy and you have ruled out medical causes, NADH is a lower-evidence option than NMN. It may still help some individuals, but the mechanism is less certain and the biomarker confirmation is weaker.

People with certain medical conditions—cancer, active infections, or severe liver disease—should be cautious with either compound. NAD⁺ fuels PARP activity during DNA repair and supports cell proliferation. In theory, raising NAD⁺ in a tumor microenvironment could be counterproductive, though this is largely speculative in humans. Anyone with a serious medical condition should consult a clinician before starting NAD⁺ precursors.

Form, Dose, and Practical Selection

If you choose NMN, the human trials provide a useful dosing anchor. Most positive studies used 250–500 mg per day. Irie et al. (2020) showed that even 100 mg raised blood metabolites, while Liao et al. (2021) used up to 600 mg for athletic populations. A product delivering 1000 mg per capsule, such as Bio:sudo NMN 1000mg, supplies a dose at the upper end of the studied range and may be appropriate for individuals who prefer once-daily dosing or who weigh more than the average trial participant. There is no evidence that 1000 mg is superior to 250 mg, but the safety profile in the published trials suggests that this dose is well tolerated in healthy adults over 6–12 weeks.

NADH is typically sold in much smaller doses—5–10 mg—often as an enteric-coated or sublingual tablet to protect it from gastric degradation. The lower dose is not a sign of potency; it reflects the larger molecular weight of NADH and the uncertainty about how much reaches systemic circulation. If you try NADH, look for formulations that specify stability data and, ideally, have published pharmacokinetic profiles. Few meet this standard.

For readers who want a deeper comparison of how different NAD⁺ precursors are absorbed and converted, see our guide on Bioavailability Explained. If you are weighing NMN against NR or nicotinamide as well, our NAD Precursor Comparison breaks down the enzymatic steps and trial data for each form.

Practical Takeaways

• NMN has multiple human RCTs showing dose-dependent rises in blood NAD⁺ metabolites and functional improvements in insulin sensitivity, muscle performance, and aerobic capacity.
• NADH has a weaker human evidence base for NAD⁺ elevation; its proposed benefits rely more on direct electron-donor or antioxidant mechanisms that are not well validated in vivo.
• If your goal is to raise intracellular NAD⁺ using the best current human data, NMN is the more rational choice.
• Doses of 250–500 mg NMN daily have been most commonly studied; 1000 mg formulations are available for those who prefer higher-dose, once-daily regimens, though direct comparative efficacy at this dose has not been tested.
• NADH may still be worth exploring for specific fatigue-related complaints, but expectations should be modest and the evidence acknowledged as limited.
• Neither supplement has been proven to extend human lifespan. Functional and metabolic benefits are the only supported outcomes, and they are modest in magnitude.

Bottom Line

The NMN vs NADH debate is not a tie. NMN enters the cell as a direct NAD⁺ precursor and has been validated in multiple human trials for raising NAD⁺ metabolites and improving clinically relevant endpoints. NADH is biochemically further from the NAD⁺ synthesis pathway and lacks comparable pharmacokinetic and functional evidence in humans. If you are selecting a supplement to support NAD⁺ biology, the evidence currently points toward NMN. For a broader view of how NMN compares to other NAD⁺ boosters, see our article on NMN vs NAD Supplement.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---